Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: Metformin Hydrochloride Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. US FDA label
Kidney dosing: Metformin (single-agent)Show full dosing details
- eGFR ≥60
- Usual dosing. Assess kidney function before starting and periodically (label).
- eGFR 30–59
- eGFR 45–59: usual dose; consider dose reduction if at high risk of lactic acidosis. eGFR 30–44: label advises not to start; if continuing, reduce to a maximum of 1,000 mg/day (KDIGO 2022; ADA-KDIGO 2022). Recheck eGFR every 3 to 6 months.
- eGFR 15–29
- Contraindicated (label). Stop if eGFR falls below 30.
- eGFR <15 (not on dialysis)
- Contraindicated (label).
- Hemodialysis (intermittent)
- Contraindicated (eGFR <30 per label).
- Peritoneal dialysis
- Contraindicated (eGFR <30 per label).
- CRRT
- Not appropriate; contraindicated in severe kidney impairment (label).
- Dialyzable? Yes: dialyzable with clearance up to 170 mL/min under good hemodynamic conditions; hemodialysis may help remove drug in suspected overdose (label).
- Monitoring eGFR before starting and at least periodically; more often in older adults. Stop before or at the time of iodinated contrast in at-risk patients per label. Hold temporarily during acute illness with dehydration, sepsis, hypoxia or acute heart failure, during procedures with restricted food or fluid intake, and for acute kidney injury; restart when eating and kidney function is stable (label 5.1).
From the Metformin monograph (renalcarematters.com, reviewed).
Use: Type 2 diabetes renalcarematters.com, reviewed
Kidney dosing: Teneligliptin (single-agent)Show full dosing details
- CrCl ≥60 mL/min
- Usual: 20 mg once daily; may increase to 40 mg once daily with close monitoring (Thai SmPC).
- CrCl 30–59 mL/min
- The label gives no kidney dose change; exposure (AUC) was about 1.25-, 1.68- and 1.49-fold higher in mild, moderate and severe impairment (Thai SmPC). A dedicated PK study found no need for adjustment through end-stage kidney disease (Halabi 2013). The 40 mg dose was not studied in kidney impairment; increase only with close monitoring.
- CrCl 15–29 mL/min
- The label gives no kidney dose change; exposure (AUC) was about 1.25-, 1.68- and 1.49-fold higher in mild, moderate and severe impairment (Thai SmPC). A dedicated PK study found no need for adjustment through end-stage kidney disease (Halabi 2013). The 40 mg dose was not studied in kidney impairment; increase only with close monitoring.
- CrCl <15 mL/min (not on dialysis)
- The label gives no kidney dose change; exposure (AUC) was about 1.25-, 1.68- and 1.49-fold higher in mild, moderate and severe impairment (Thai SmPC). A dedicated PK study found no need for adjustment through end-stage kidney disease (Halabi 2013). The 40 mg dose was not studied in kidney impairment; increase only with close monitoring.
- Hemodialysis (intermittent)
- No dose change in the label; end-stage kidney failure AUC about 1.16-fold; hemodialysis removed 15.6% of the dose (Thai SmPC). Dialysis timing not critical.
- Peritoneal dialysis
- No PD data; no change expected from end-stage kidney failure data (AUC about 1.16-fold).
- CRRT
- No data. Insulin is usual in critical illness.
- Dialyzable? Partly: hemodialysis removed 15.6% of the dose (Thai SmPC).
- Monitoring Hypoglycemia with a sulfonylurea or insulin (lower their dose). Avoid with QT prolongation or torsades history; caution with class IA or III antiarrhythmics. Persistent severe abdominal pain (pancreatitis), intestinal obstruction in those with prior abdominal surgery (Thai SmPC). Caution in severe hepatic impairment (no experience). In dialysis patients, check QTc and electrolytes when other QT risk factors are present.
From the Teneligliptin monograph (renalcarematters.com, reviewed).
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Extended-release tablet: 1 g/20 mg, 500 mg/20 mg
Registered products in the Philippines
2 products registered with the Food and Drug Administration (FDA) Philippines list Metformin + Teneligliptin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
TenelimetMetformin Hydrochloride + Teneligliptin (as hydrobromide hydrate) | 1 g/20 mg Extended-Release TabletAlu-Alu Blister Pack of 10's (Box of 30's) | RxVAT-exempt | Ajanta Pharma LimitedIndia | Ajanta Pharma Philippines Inc. | DR-XY49309 | Jan 13, 2030 | |
TenelimetMetformin Hydrochloride + Teneligliptin (as hydrobromide hydrate) | 500 mg/20 mg Extended-Release TabletAlu/Alu Blister Pack of 10's (Box of 30's) | RxVAT-exempt | Ajanta Pharma LimitedIndia | Ajanta Pharma Philippines Inc. | DR-XY49310 | Jan 13, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .